FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar
On May 10, 2026, Shanghai Henlius Biotech announced that the FDA has approved its IND for a proposed biosimilar, HLX05-N, to Eli Lilly’s ERBITUX (cetuximab) product for the treatment of metastatic colorectal cancer (mCRC). ERBITUX is approved in the United States for the treatment of KRAS wild-type, epidermal growth factor receptor (EGFR)-expressing mCRC, among other indications.
Henlius indicated that it plans to advance the program through clinical development and pursue a future BLA submission to the FDA. To date, no biosimilars of cetuximab have been approved in the United States or Europe.
The post FDA Approves Shanghai Henlius Biotech IND for Cetuximab Biosimilar appeared first on Big Molecule Watch.